{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T02:40:24Z","timestamp":1724726424723},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.schres.2024.01.018","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T16:48:34Z","timestamp":1705510114000},"page":"372-377","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks"],"prefix":"10.1016","volume":"264","author":[{"given":"Ryan E.","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2024.01.018_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3563910","article-title":"Drug-free research in schizophrenia: an overview of the controversy","volume":"18","author":"Appelbaum","year":"1996","journal-title":"IRB"},{"year":"1781","series-title":"The Principles of Morals and Legislation","author":"Bentham","key":"10.1016\/j.schres.2024.01.018_bb0010"},{"key":"10.1016\/j.schres.2024.01.018_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1-3","key":"10.1016\/j.schres.2024.01.018_bb0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.schres.2007.11.022","article-title":"A direct comparison of research decision-making capacity: schizophrenia\/schizoaffective, medically ill, and non-ill subjects","volume":"99","author":"Candilis","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.01.018_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1997.01830170015002","article-title":"The rationale and ethics of medication-free research in schizophrenia","volume":"54","author":"Carpenter","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.01.018_bb0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1176\/appi.ajp.160.2.356","article-title":"The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia","volume":"160","author":"Carpenter","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.01.018_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"issue":"6549","key":"10.1016\/j.schres.2024.01.018_bb0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.293.6549.726","article-title":"Does short term placebo treatment of chronic schizophrenia produce long term harm?","volume":"293","author":"Curson","year":"1986","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"issue":"2","key":"10.1016\/j.schres.2024.01.018_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00001504-200503000-00003","article-title":"Emerging findings in ethics of schizophrenia research","volume":"18","author":"Dunn","year":"2005","journal-title":"Curr. Opin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.01.018_bb0050","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/appi.ajp.163.3.500","article-title":"Assessment of therapeutic misconception in older schizophrenia patients with a brief instrument","volume":"163","author":"Dunn","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2024.01.018_bb0055","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/schbul\/sbn003","article-title":"Worth the risk? Relationship of incentives to risk and benefit perceptions and willingness to participate in schizophrenia research","volume":"35","author":"Dunn","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2024.01.018_bb0060","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases","volume":"133","author":"Ellenberg","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.schres.2024.01.018_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2024.01.018_bb0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4088\/JCP.12m07997","article-title":"Participants with schizophrenia retain the information necessary for informed consent during clinical trials","volume":"74","author":"Fischer","year":"2013","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2024.01.018_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1748-720X.1996.tb01860.x","article-title":"Placebo orthodoxy in clinical research II: ethical, legal, and regulatory myths","volume":"24","author":"Freedman","year":"1996","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.schres.2024.01.018_bb0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1748-720X.1996.tb01859.x","article-title":"Placebo orthodoxy in clinical research I: empirical and methodological myths","volume":"24","author":"Freedman","year":"1996","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.schres.2024.01.018_bb0085","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia","volume":"174","author":"Goff","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.01.018_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1748-720X.1985.tb00886.x","article-title":"The substituted judgment approach: its difficulties and paradoxes in mental health settings","volume":"13","author":"Gutheil","year":"1985","journal-title":"Law Med. Health Care"},{"year":"1785","series-title":"Groundwork of the Metaphysic of Morals","author":"Kant","key":"10.1016\/j.schres.2024.01.018_bb0095"},{"key":"10.1016\/j.schres.2024.01.018_bb0100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jpsychires.2020.08.003","article-title":"Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis: discontinuation in antipsychotic trials","volume":"130","author":"Kishi","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.01.018_bb0105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0924-9338(01)00600-9","article-title":"The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective","volume":"16","author":"Laughren","year":"2001","journal-title":"Eur. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2024.01.018_bb0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamapsychiatry.2019.0275","article-title":"Are placebo-controlled, relapse prevention trials in schizophrenia research still necessary or ethical?","volume":"76","author":"Lawrence","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2024.01.018_bb0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2020.11.022","article-title":"A historical review of placebo-controlled, relapse prevention trials in schizophrenia: the loss of clinical equipoise","volume":"229","author":"Lawrence","year":"2021","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.schres.2024.01.018_bb0120","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41386-019-0440-6","article-title":"Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2024.01.018_bb0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.01.018_bb0130","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(02)08277-6","article-title":"Placebo-controlled trials and the Declaration of Helsinki","volume":"359","author":"Lewis","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2024.01.018_bb0135","first-page":"19","article-title":"Ethical dilemmas in clinical research with human subjects: an investigator's perspective","volume":"32","author":"Lieberman","year":"1996","journal-title":"Psychopharmacol. Bull."},{"year":"1861","series-title":"Utilitarianism","author":"Mill","key":"10.1016\/j.schres.2024.01.018_bb0140"},{"key":"10.1016\/j.schres.2024.01.018_bb0145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0006-3223(00)00833-7","article-title":"Placebo-controlled trials in psychiatric research: an ethical perspective","volume":"47","author":"Miller","year":"2000","journal-title":"Biol. Psychiatry"},{"author":"National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research","key":"10.1016\/j.schres.2024.01.018_bb0150"},{"issue":"25","key":"10.1016\/j.schres.2024.01.018_bb0155","article-title":"Clinical trial of new drug for schizophrenia","volume":"384","author":"Neary","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.schres.2024.01.018_bb0160","article-title":"The authors reply","volume":"384","author":"Paul","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.schres.2024.01.018_bb0165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/medicina55070361","article-title":"Suicide in schizophrenia: an educational overview","volume":"55","author":"Sher","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.schres.2024.01.018_bb0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"7070","key":"10.1016\/j.schres.2024.01.018_bb0175","first-page":"1448","volume":"313","author":"The Nuremberg Code (1947)","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2024.01.018_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0920-9964(98)00127-3","article-title":"Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?","volume":"35","author":"Weijer","year":"1999","journal-title":"Schizophr. Res."},{"author":"World Medical Association","key":"10.1016\/j.schres.2024.01.018_bb0185"},{"issue":"9","key":"10.1016\/j.schres.2024.01.018_bb0190","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2024.01.018_bb0195","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0006-3223(99)00227-9","article-title":"The long-term effects of placebo in patients with chronic schizophrenia","volume":"46","author":"Wyatt","year":"1999","journal-title":"Biol. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424000185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424000185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T01:46:30Z","timestamp":1724723190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424000185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"alternative-id":["S0920996424000185"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.01.018","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}